High expression of the hypoxia marker CAIX in soft tissue sarcoma was found to be associated with poor survival in the Phase III adjuvant RT VorteX trial but two other hypoxia markers Hif-1a and GLUT1 were not (Forker et al., 2018). Here, SLC2A1 is linked to soft tissue sarcoma.